KDM1A was found to facilitate immunosuppression by upregulating PD-L1 expression and KDM1A-targeting therapy could reduce acquired resistance to sorafenib and improve HCC therapeutic efficacy [56, 57]. This evidence concerns the gene CD274 and hepatocellular carcinoma.